Rich Nicole E
Division of Digestive and Liver Diseases, Department of Internal Medicine, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, 5959 Harry Hines Boulevard, Professional Office Building 1, Suite 4.420G, Dallas, TX 75390-8887, USA.
Surg Oncol Clin N Am. 2024 Jan;33(1):1-12. doi: 10.1016/j.soc.2023.06.004. Epub 2023 Aug 31.
Globally, hepatocellular carcinoma (HCC) is a major cause of cancer-related death and a leading cause of morbidity and mortality in patients with chronic liver disease and cirrhosis. The predominant cause of HCC is shifting from viral to nonviral causes, in parallel with the high global prevalence of nonalcoholic fatty liver disease and increasing alcohol consumption in many countries. There have been promising recent advances in the treatment of all stages of HCC; however, improvements in early detection, increased utilization of HCC surveillance, and equitable access to HCC therapies are needed to curb increases in HCC mortality.
在全球范围内,肝细胞癌(HCC)是癌症相关死亡的主要原因,也是慢性肝病和肝硬化患者发病和死亡的主要原因。HCC的主要病因正在从病毒病因向非病毒病因转变,这与全球非酒精性脂肪性肝病的高患病率以及许多国家酒精消费量的增加同时发生。近年来,HCC各阶段的治疗都取得了令人鼓舞的进展;然而,需要改进早期检测、提高HCC监测的利用率,并公平地获得HCC治疗,以遏制HCC死亡率的上升。